The FDA has granted approval for Lecanemab (Leqembi)
Here are the basic facts you should know about this medication
1. Indicated only for patients with early Alzheimers with elevated beta-amyloid
2. It is not curative; it appears to modestly slow disease progression.
3. It will not restore cognitive disfunction.
4. A PET scan or LP is required before starting the medication.
5. The medication is given by IV infusion every other week.
5. The cost is $26,500 per year for the medication.
6. There will be additional costs for the infusion and follow up brain scans.
7. Side effects include brain swelling and bleeding.

Detailed Article on Lecanemab Controversy

Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care
https://n.neurology.org/content/neurology/101/14/610.full.pdf

More information can be found here:
Manufacturer Website: https://www.leqembi.com/
Alzheimers Association: https://www.alz.org/alzheimers-dementia/treatments/lecanemab-leqembi
CMS/Medicare Coverage: https://www.cms.gov/newsroom/fact-sheets/cms-announces-new-details-plan-cover-new-alzheimers-drugs
Neurology Live: https://www.neurologylive.com/view/lecanemab-impact-care-diagnosis-future-alzheimer-disease-treatment
Dr Esther Choo: https://www.msnbc.com/opinion/msnbc-opinion/leqembi-alzheimers-drug-benefits-expectations-rcna93524
NEJM Original Study: https://www.nejm.org/doi/full/10.1056/NEJMoa2212948